N/A Completed N=22 Randomized Double-blind Treatment

Treatment of Hypovitaminosis D in Rheumatoid Arthritis

Rheumatoid Arthritis · Hypovitaminosis D

Source: ClinicalTrials.gov NCT00423358 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2015

Primary outcomePrimary: Parathyroid Hormone Level — 19; 20 pg/mL

Summary

This study recruits individuals with rheumatoid arthritis (RA) and low vitamin D concentrations. Subjects are dosed with vitamin D or placebo for one year. Primary outcome is change in bone turnover markers, additionally, bone mineral density and parameters of RA status are evaluated throughout the study.

Outcome Measures

Outcome	Result	p-value
PRIMARY Parathyroid Hormone Level	19; 20	—
SECONDARY Bone Mineral Density	0.970; 1.151	—
SECONDARY Short Form 36 Survey	39.1; 47.7	—

Eligibility Criteria

Inclusion Criteria

Rheumatology

Exclusion Criteria

Bisphosphonate therapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00423358). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.